GlobeNews Wire

Constellation Software Inc. Announces Results of Voting for Directors at Annual General Shareholders Meeting

May 15, 2026 20:23 ET  | Source: Constellation Software Inc. TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- Constellation Software Inc.…

2 weeks ago

Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress

Agoura Hills, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a clinical-stage…

2 weeks ago

Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility

May 15, 2026 09:00 ET  | Source: Sana Biotechnology, Inc SEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology,…

2 weeks ago

Vaso Corporation Announces Financial Results for First Quarter of 2026

May 15, 2026 09:00 ET  | Source: Vaso Corporation PLAINVIEW, N.Y., May 15, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”)…

2 weeks ago

Banqup Group decides to postpone Extraordinary General Meeting of 19 May 2026

La Hulpe, Belgium – 15 May 2026, 7:00 CET – INSIDE INFORMATION – Banqup Group SA, (Euronext: BANQ) (Banqup, Company),…

3 weeks ago

Berto Acquisition Corp. II Announces Pricing of Upsized $274,000,000 Initial Public Offering

May 14, 2026 23:08 ET  | Source: BERTO ACQUISITION CORP. II NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Berto…

3 weeks ago

FormFactor Announces Participation at Upcoming Conferences

May 14, 2026 22:00 ET  | Source: FormFactor, Inc. LIVERMORE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- FormFactor, Inc. (Nasdaq:…

3 weeks ago

Adaptin Bio Shares (Ticker: APTN) Commence Trading on the OTCQB

CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Adaptin Bio, Inc. (OTCQB: APTN), (“Adaptin” or the “Company”), a biotechnology company…

3 weeks ago

Rarecells Recognized Among Top 5 Disruptive Health Technologies with the Potential to Change the World by Maynooth Universitys Innovation Value Institute

NEW YORK and PARIS, May 14, 2026 (GLOBE NEWSWIRE) -- Rarecells, a pioneer in liquid biopsy technologies for early cancer…

3 weeks ago

Imviva Biotech Presents Data Demonstrating Durable Clinical Responses from Ongoing Phase 1/2 Study of CTA313 in Systemic Lupus Erythematosus at ASGCT 2026

100% of patients treated with CTA313 achieved an SRI-4 response, with half achieving remission May 14, 2026 11:43 ET  |…

3 weeks ago